Research programme: mitochondrial HDAC1 Inhibitors - Medical University of South Carolina/Neuroene Therapeutics
Alternative Names: MitoDakLatest Information Update: 01 Jul 2021
At a glance
- Originator Medical University of South Carolina
- Developer Medical University of South Carolina; Neuroene Therapeutics
- Class Cardiovascular therapies
- Mechanism of Action HDAC1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Myocardial reperfusion injury
Most Recent Events
- 01 Jul 2021 Neuroene Therapeutics has patent protection for multiple analogues in various indications and the corresponding methods including Myocardial reperfusion injury (Neuroene Therapeutics website, July 2021)
- 01 Jul 2021 Neuroene Therapeutics has patents pending for multiple analogues in various indications and the corresponding methods including Myocardial reperfusion injury (Neuroene Therapeutics website, July 2021)
- 01 Jul 2021 Early research in Myocardial reperfusion injury in USA (unspecified route) before July 2021 (Neuroene Therapeutics website, July 2021)